Organogenesis is a drug manufacturers-specialty & generic business based in the US. Organogenesis shares (ORGO) are listed on the NASDAQ and all prices are listed in US Dollars. Organogenesis employs 950 staff and has a trailing 12-month revenue of around $463.9 million.
How to buy Organogenesis stock
- Choose a stock trading platform. Use our comparison table or choose from our Top Picks below.
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds unto your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – ORGO. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
SoFi Invest
- Trade stocks for $0 and no annual fee
- Start trading with a $0 minimum deposit
- Get up to $1,000 when you fund a new account within 30 days
eToro
- Easy to use platform with low fees
- Social trading allows you to copy popular portfolios
- FINDER EXCLUSIVE: Get $15 when you sign up and deposit $100
Robinhood
- Get free stock upon signup
- Earn 4% interest on uninvested cash with Robinhood Gold
- Get 1% match on contributions to a Robinhood IRA
Organogenesis stock price (NASDAQ: ORGO)
Use our graph to track the performance of ORGO stocks over time.Organogenesis shares at a glance
Latest market close | $2.80 |
---|---|
52-week range | $2.23 - $9.27 |
50-day moving average | $2.64 |
200-day moving average | $4.16 |
Wall St. target price | $11.00 |
PE ratio | 6.1042 |
Dividend yield | $0 (0%) |
Earnings per share (TTM) | $0.48 |
Buy Organogenesis stocks from these brokerages
Compare special offers, low fees and a wide range of types of investments among top trading platforms.Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
Is it a good time to buy Organogenesis stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Organogenesis price performance over time
Historical closes compared with the close of $2.8 from 2023-02-03
1 week (2023-01-30) | 13.36% |
---|---|
1 month (2023-01-06) | 6.06% |
3 months (2022-11-07) | -14.63% |
6 months (2022-08-05) | -54.77% |
1 year (2022-02-07) | -62.57% |
---|---|
2 years (2021-02-05) | -78.44% |
3 years (2020-02-07) | 4.7 |
5 years (2018-02-06) | 10.05 |
Is Organogenesis stock undervalued or overvalued?
Valuing Organogenesis stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Organogenesis's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Organogenesis's P/E ratio
Organogenesis's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 6x. In other words, Organogenesis shares trade at around 6x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Organogenesis's EBITDA
Organogenesis's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $53.4 million.
The EBITDA is a measure of a Organogenesis's overall financial performance and is widely used to measure a its profitability.
Organogenesis financials
Revenue TTM | $463.9 million |
---|---|
Operating margin TTM | 9.14% |
Gross profit TTM | $353.9 million |
Return on assets TTM | 6.4% |
Return on equity TTM | 26.82% |
Profit margin | 12.88% |
Book value | $1.96 |
Market capitalisation | $383.6 million |
TTM: trailing 12 months
Organogenesis share dividends
We're not expecting Organogenesis to pay a dividend over the next 12 months.
Organogenesis share price volatility
Over the last 12 months, Organogenesis's shares have ranged in value from as little as $2.23 up to $9.27. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Organogenesis's is 1.5011. This would suggest that Organogenesis's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Organogenesis overview
Organogenesis Holdings Inc. , a regenerative medicine company develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane wound covering in which viable cells growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, and cytokines; NuShield, a wound covering tissue includes both amnion and chorion membranes for spongy/intermediate layer intact; PuraPly , a antimicrobial barrier that enables conformability and fluid drainage; and Novachor, an amniotic membrane wound covering in which viable cells, growth factors/cytokines, and ECM proteins are preserved. Its surgical and sports medicine products comprise NuCel, a dehydrated placental tissue surgically applied to the target tissue to support native healing; ReNu, a cryopreserved suspension used to support healing of soft tissues; and FiberOS and OCMP used as a bone void filler primarily in orthopedic and neurosurgical applications. The company's pipeline products include PuraPly XT and PuraPly MZ to treat chronic, acute, and open wounds; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales force and independent agencies. The company was founded in 1985 and is headquartered in Canton, Massachusetts.
Frequently asked questions
What percentage of Organogenesis is owned by insiders or institutions?Currently 50.572% of Organogenesis shares are held by insiders and 43.092% by institutions. How many people work for Organogenesis?
Latest data suggests 950 work at Organogenesis. When does the fiscal year end for Organogenesis?
Organogenesis's fiscal year ends in December. Where is Organogenesis based?
Organogenesis's address is: 85 Dan Road, Canton, MA, United States, 02021 What is Organogenesis's ISIN number?
Organogenesis's international securities identification number is: US68621F1021 What is Organogenesis's CUSIP number?
Organogenesis's Committee on Uniform Securities Identification Procedures number is: 68621F102
More guides on Finder
-
How to buy Neuraxis (NRXS) stock when it goes public
Everything we know about the Neuraxis IPO, plus information on how to buy in.
-
How to buy TXO Energy (TXO) stock
Everything we know about the TXO Energy IPO, plus information on how to buy in.
-
How to buy Brera (BREA) stock
Everything we know about the Brera IPO, plus information on how to buy in.
-
How to invest in the S&P 500
What you need to know about investing in the leading indicator for the overall US stock market.
-
How to buy IPO stock
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
-
How to buy Novo Integrated Sciences stock
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
-
How do ETFs work?
Your simple and straightforward guide to ETFs, how they work and the different types available.
-
What is stock lending?
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
-
How to buy SONDORS (SODR) stock when it goes public
Everything we know about the SONDORS IPO, plus information on how to buy in.
-
How to buy Bullfrog AI Holdings (BFRG) stock when it goes public
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.
Ask an Expert